

REMARKS/ARGUMENTS

The Office Action sets forth a twenty-way restriction requirement. Applicants elect, without traverse, the subject matter of Group VIII (drawn to a compound of claim 1 wherein A is (A2) and B is 2,4-dioxothiazolidin-5-yl) for further examination.


With respect to the required species selection, Applicants elect the compound of Example 18 (Example Compound No. 2-18), which is identified in the present specification by the chemical name 5-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1,3-thiazolidine-2,4-dione. Pending claims 1, 5, 7, and 10 of Group VIII read upon the selected species. Applicants note that the Examiner has not included claim 10 in Group VIII; however, claim 10 specifically recites the selected species and, therefore, is directed to the elected subject matter (i.e., a compound of claim 1 wherein A is (A2) and B is 2,4-dioxothiazolidin-5-yl). Accordingly, Applicants respectfully submit that claim 10 should have been identified, and should be treated, as part of Group VIII.

Applicants request the rejoinder and consideration by the Examiner of any withdrawn claims that depend on, or otherwise recite all of the limitations of, an allowed claim.

In addition, Applicants reserve the right to pursue any non-elected subject matter that is ultimately canceled in the present application in one or more divisional applications in accordance with U.S. patent practice.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



John Kilyk, Jr., Reg. No. 30,763
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6731
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: August 29, 2007